Published in Neuropsychopharmacology on January 01, 2003
NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl) (2003) 2.28
In psychosis, cortical interneurons overexpress DNA-methyltransferase 1. Proc Natl Acad Sci U S A (2005) 1.72
The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. Proc Natl Acad Sci U S A (2006) 1.71
Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry (2015) 1.22
Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone. Schizophr Bull (2007) 1.05
Biological, life course, and cross-cultural studies all point toward the value of dimensional and developmental ratings in the classification of psychosis. Schizophr Bull (2007) 1.02
Prenatal exposure to an NMDA receptor antagonist, MK-801 reduces density of parvalbumin-immunoreactive GABAergic neurons in the medial prefrontal cortex and enhances phencyclidine-induced hyperlocomotion but not behavioral sensitization to methamphetamine in postpubertal rats. Psychopharmacology (Berl) (2007) 1.00
Disease- and age-related changes in histone acetylation at gene promoters in psychiatric disorders. Transl Psychiatry (2011) 0.97
Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room. Health Qual Life Outcomes (2011) 0.97
Polypharmacy for schizophrenia. Curr Opin Psychiatry (2013) 0.94
Informing DSM-5: biological boundaries between bipolar I disorder, schizoaffective disorder, and schizophrenia. BMC Med (2013) 0.93
Chromatin, DNA methylation and neuron gene regulation--the purpose of the package. J Psychiatry Neurosci (2005) 0.91
The potential role of lamotrigine in schizophrenia. Psychopharmacology (Berl) (2005) 0.87
Significant Effect of Valproate Augmentation Therapy in Patients With Schizophrenia: A Meta-analysis Study. Medicine (Baltimore) (2016) 0.85
Antipsychotics prescribing patterns of patients with schizophrenia admitted to korean general hospital psychiatric unit: 2001 to 2008. Clin Psychopharmacol Neurosci (2011) 0.85
Pharmacotherapy of schizophrenic patients: preponderance of off-label drug use. PLoS One (2008) 0.83
The effectiveness of anticonvulsants in psychiatric disorders. Dialogues Clin Neurosci (2008) 0.82
Unbalanced statistical analysis of combined divalproex and antipsychotic therapy for schizophrenia. Neuropsychopharmacology (2004) 0.78
Extended-release divalproex in bipolar and other psychiatric disorders: A comprehensive review. Neuropsychiatr Dis Treat (2007) 0.76
Epigenetic signaling in schizophrenia. Cell Signal (2015) 0.76
Functional hallucinations in schizophrenia responding to adjunctive sodium valproate. Indian J Psychol Med (2012) 0.76
Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology (2003) 0.76
Augmentation of olanzapine in treatment-resistant schizophrenia. J Psychiatry Neurosci (2005) 0.75
Lithium or Valproate Adjunctive Therapy to Second-generation Antipsychotics and Metabolic Variables in Patients With Schizophrenia or Schizoaffective Disorder. J Psychiatr Pract (2016) 0.75
Valproate increases dopamine transporter expression through histone acetylation and enhanced promoter binding of Nurr1. Neuropharmacology (2017) 0.75
The brief negative symptom scale: psychometric properties. Schizophr Bull (2010) 2.27
A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry (2002) 2.26
Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone. Psychiatr Serv (2004) 1.68
Methodological issues in negative symptom trials. Schizophr Bull (2011) 1.28
A double-blind, randomized, placebo-controlled trial of divalproex extended-release in the treatment of bipolar disorder in children and adolescents. J Am Acad Child Adolesc Psychiatry (2009) 1.14
Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Sleep Med (2007) 1.06
Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology (2003) 1.05
A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. J Psychiatr Res (2007) 1.05
The safety and early efficacy of oral-loaded divalproex versus standard-titration divalproex, lithium, olanzapine, and placebo in the treatment of acute mania associated with bipolar disorder. J Clin Psychiatry (2003) 1.05
An open-label trial of divalproex in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry (2002) 1.04
Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers. Epilepsy Res (2002) 1.01
Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol (2003) 0.99
Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia. Neuropsychopharmacology (2008) 0.97
Acute pancreatitis coincident with valproate use: a critical review. Epilepsia (2002) 0.89
From clinical research to clinical practice: a 4-year review of ziprasidone. CNS Spectr (2005) 0.88
Divalproex extended-release versus the original divalproex tablet: results of a randomized, crossover study of well-controlled epileptic patients with primary generalized seizures. Epilepsy Res (2002) 0.88
Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease. Clin Neuropharmacol (2005) 0.85
Valproic acid induces manifestations of simultaneous dopamine enhancement and reduction in schizophrenia. Neuropsychopharmacology (2004) 0.83
Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. Schizophr Res (2013) 0.82
Bioequivalence in development of antiepileptic drugs. Epilepsy Res (2006) 0.82
A comparative analysis between site-based and centralized ratings and patient self-ratings in a clinical trial of Major Depressive Disorder. J Psychiatr Res (2013) 0.81
Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes. J Clin Psychiatry (2003) 0.81
Ratings of early major depressive disorder symptom change during a brief psychiatric hospitalization. Psychiatr Q (2005) 0.80
A randomized, placebo-controlled, multicenter study of divalproex sodium extended-release in the acute treatment of mania. J Clin Psychiatry (2010) 0.80
Development and psychometric evaluation of a clinical global impression for schizoaffective disorder scale. Innov Clin Neurosci (2012) 0.79
A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. J Clin Psychiatry (2010) 0.79
Effects of adjunct valproic acid on clinical symptoms and saccadic eye movements in schizophrenia. Hum Psychopharmacol (2011) 0.78
Psychosis in mania: specificity of its role in severity and treatment response. J Clin Psychiatry (2004) 0.78
Effects of haloperidol on cognition in schizophrenia patients depend on baseline performance: a saccadic eye movement study. Prog Neuropsychopharmacol Biol Psychiatry (2011) 0.78
Updated treatment algorithm. J Emerg Med (2004) 0.77
Long-term safety of divalproex sodium extended-release in children and adolescents with bipolar I disorder. J Child Adolesc Psychopharmacol (2009) 0.77
Future directions in research. J Emerg Med (2004) 0.77
Standard therapies for acute agitation. J Emerg Med (2004) 0.77
Safety and effectiveness of long-term treatment with diazepam auto-injector administered by caregivers in an outpatient setting for the treatment of acute repetitive seizures. Epilepsia (2014) 0.76
Safety of medications used to treat acute agitation. J Emerg Med (2004) 0.76
Effects of concurrent intravenous morphine sulfate and naltrexone hydrochloride on end-tidal carbon dioxide. Harm Reduct J (2012) 0.75
Electronic evaluation forms and the rate of completion of residency evaluations. Acad Psychiatry (2012) 0.75
Novel therapies for treating acute agitation. J Emerg Med (2004) 0.75
Occurrence of psychosis in patients with epilepsy randomized to tiagabine or placebo treatment. Epilepsia (2002) 0.75
Who receives antidepressants and what impact do they have? An acute-care study. Psychiatr Q (2006) 0.75
The Efficacy of Cariprazine on Cognition: A Post Hoc Analysis From Phase II/III Clinical Trials in Bipolar Mania, Bipolar Depression, and Schizophrenia. CNS Spectr (2022) 0.75
Assessing subjective and physiologic effects following intranasal administration of a new formulation of immediate release oxycodone HCl (Oxecta™) tablets in nondependent recreational opioid users. J Opioid Manag (2012) 0.75
Intramuscular antipsychotics: clinical experience review. J Emerg Med (2004) 0.75